Home > Journals > Minerva Endocrinologica > Past Issues > Minerva Endocrinologica 2006 March;31(1) > Minerva Endocrinologica 2006 March;31(1):47-60

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe PROMO
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Reprints

 

REVIEWS   

Minerva Endocrinologica 2006 March;31(1):47-60

Copyright © 2006 EDIZIONI MINERVA MEDICA

language: English

Aromatase in the context of breast and endometrial cancer. A review

Jongen V. H. W. M. 1, Hollema H. 2, Van Der Zee A. G. J. 3, Heineman M. J. 3

1 Departments of Obstetrics and Gynaecology, Diaconessenhuis Meppel, Meppel, The Netherlands 2 Department of Pathology, and Laboratory Medicine, University Hospital Groningen, The Netherlands 3 Departments of Obstetrics and Gynaecology, University Hospital Groningen, The Netherlands


PDF


Generally, estrogens are considered to be involved in the neoplastic transformation of endometrium. After the menopause these estrogens mainly originate from conversion of adrenal androgens by aromatization in body fat. However, in case of stromal hyperplasia of the ovaries, it cannot be excluded that production of aromatizable androgens by postmenopausal ovaries leads to increased availability of androgen precursors for intratumoral estrogen synthesis in the endometrial tissue as well. The local presence of androgens and the local expression and activity of aromatase is considered important for this steroidogenesis. In this review, we will discuss the available evidence that androgens, produced in hyperplastic ovarian stroma or body fat tissues, play a role in the development of endometrial cancer through conversion into estrogens, a reaction catalyzed in the endometrium by the enzyme aromatase cytochrome P450. As the presence of aromatase appeared to be a pathophysiological factor in the formation of breast cancer, the latter will be evaluated in relation to the development of endometrioid endometrial cancer as well, since both disorders appear partly estrogen dependent. As treatment with aromatase inhibitors appeared feasible in breast cancer, current knowledge of comparable treatment modalities in hormone dependent endometrial cancer will be reviewed.

top of page